Haemonetics Corp (HAE)

$73.24

-1.34

(-1.8%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $72.72
    $74.80
    $73.24
    downward going graph

    0.71%

    Downside

    Day's Volatility :2.78%

    Upside

    2.09%

    downward going graph
  • $70.74
    $97.97
    $73.24
    downward going graph

    3.41%

    Downside

    52 Weeks Volatility :27.79%

    Upside

    25.24%

    downward going graph

Returns

PeriodHaemonetics CorpSector (Health Care)Index (Russel 2000)
3 Months
-14.45%
5.1%
0.0%
6 Months
-5.8%
4.9%
0.0%
1 Year
-16.69%
16.6%
0.0%
3 Years
13.57%
13.2%
-22.3%

Highlights

Market Capitalization
3.8B
Book Value
$17.7
Earnings Per Share (EPS)
2.19
PE Ratio
33.44
PEG Ratio
1.19
Wall Street Target Price
112.14
Profit Margin
8.61%
Operating Margin TTM
19.64%
Return On Assets TTM
6.09%
Return On Equity TTM
12.98%
Revenue TTM
1.3B
Revenue Per Share TTM
26.26
Quarterly Revenue Growth YOY
8.0%
Gross Profit TTM
530.8M
EBITDA
314.1M
Diluted Eps TTM
2.19
Quarterly Earnings Growth YOY
-0.07
EPS Estimate Current Year
3.96
EPS Estimate Next Year
4.4
EPS Estimate Current Quarter
1.0
EPS Estimate Next Quarter
1.09

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Haemonetics Corp(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.11%

Current $73.24
Target $112.14

Company Financials

FY19Y/Y Change
Revenue
967.6M
↑ 7.04%
Net Income
55.0M
↑ 20.73%
Net Profit Margin
5.69%
↑ 0.65%
FY20Y/Y Change
Revenue
988.5M
↑ 2.16%
Net Income
76.5M
↑ 39.09%
Net Profit Margin
7.74%
↑ 2.05%
FY21Y/Y Change
Revenue
870.5M
↓ 11.94%
Net Income
79.5M
↑ 3.85%
Net Profit Margin
9.13%
↑ 1.39%
FY22Y/Y Change
Revenue
993.2M
↑ 14.1%
Net Income
43.4M
↓ 45.42%
Net Profit Margin
4.37%
↓ 4.76%
FY23Y/Y Change
Revenue
1.2B
↑ 17.67%
Net Income
115.4M
↑ 166.05%
Net Profit Margin
9.87%
↑ 5.5%
FY24Y/Y Change
Revenue
1.3B
↑ 12.01%
Net Income
117.6M
↑ 1.87%
Net Profit Margin
8.98%
↓ 0.89%
Q1 FY23Q/Q Change
Revenue
304.4M
↓ 0.29%
Net Income
29.4M
↓ 10.81%
Net Profit Margin
9.65%
↓ 1.14%
Q2 FY23Q/Q Change
Revenue
311.3M
↑ 2.27%
Net Income
41.0M
↑ 39.68%
Net Profit Margin
13.18%
↑ 3.53%
Q3 FY23Q/Q Change
Revenue
318.2M
↑ 2.2%
Net Income
24.9M
↓ 39.31%
Net Profit Margin
7.83%
↓ 5.35%
Q4 FY23Q/Q Change
Revenue
336.3M
↑ 5.68%
Net Income
31.2M
↑ 25.43%
Net Profit Margin
9.29%
↑ 1.46%
Q1 FY24Q/Q Change
Revenue
343.3M
↑ 2.09%
Net Income
20.4M
↓ 34.81%
Net Profit Margin
5.93%
↓ 3.36%
Q2 FY24Q/Q Change
Revenue
336.2M
↓ 2.07%
Net Income
38.4M
↑ 88.41%
Net Profit Margin
11.41%
↑ 5.48%
FY19Y/Y Change
Total Assets
1.3B
↑ 3.02%
Total Liabilities
606.9M
↑ 25.16%
FY20Y/Y Change
Total Assets
1.3B
↓ 0.6%
Total Liabilities
680.0M
↑ 12.05%
FY21Y/Y Change
Total Assets
1.8B
↑ 43.63%
Total Liabilities
1.1B
↑ 60.04%
FY22Y/Y Change
Total Assets
1.9B
↑ 2.19%
Total Liabilities
1.1B
↑ 2.03%
FY23Y/Y Change
Total Assets
1.9B
↑ 4.04%
Total Liabilities
1.1B
↑ 0.59%
FY24Y/Y Change
Total Assets
2.2B
↑ 13.48%
Total Liabilities
1.2B
↑ 10.64%
Q1 FY23Q/Q Change
Total Assets
1.9B
↑ 3.02%
Total Liabilities
1.1B
↑ 1.34%
Q2 FY23Q/Q Change
Total Assets
2.0B
↑ 1.42%
Total Liabilities
1.1B
↓ 1.72%
Q3 FY23Q/Q Change
Total Assets
2.0B
↑ 2.5%
Total Liabilities
1.1B
↑ 1.82%
Q4 FY23Q/Q Change
Total Assets
2.2B
↑ 9.4%
Total Liabilities
1.3B
↑ 12.48%
Q1 FY24Q/Q Change
Total Assets
2.2B
↓ 0.22%
Total Liabilities
1.2B
↓ 1.71%
Q2 FY24Q/Q Change
Total Assets
2.5B
↑ 15.73%
Total Liabilities
1.6B
↑ 32.37%
FY19Y/Y Change
Operating Cash Flow
159.3M
↓ 27.71%
Investing Cash Flow
-116.1M
↑ 84.24%
Financing Cash Flow
-50.6M
↓ 58.03%
FY20Y/Y Change
Operating Cash Flow
158.2M
↓ 0.67%
Investing Cash Flow
-57.2M
↓ 50.77%
Financing Cash Flow
-131.2M
↑ 159.16%
FY21Y/Y Change
Operating Cash Flow
108.8M
↓ 31.23%
Investing Cash Flow
-425.4M
↑ 644.09%
Financing Cash Flow
367.5M
↓ 380.05%
FY22Y/Y Change
Operating Cash Flow
172.3M
↑ 58.32%
Investing Cash Flow
-86.3M
↓ 79.7%
Financing Cash Flow
-15.7M
↓ 104.29%
FY23Y/Y Change
Operating Cash Flow
273.1M
↑ 58.51%
Investing Cash Flow
-143.8M
↑ 66.53%
Financing Cash Flow
-100.4M
↑ 537.27%
Q1 FY23Q/Q Change
Operating Cash Flow
79.6M
↑ 23.59%
Investing Cash Flow
-18.0M
↓ 50.67%
Financing Cash Flow
-1.6M
↓ 96.77%
Q2 FY23Q/Q Change
Operating Cash Flow
19.1M
↓ 76.03%
Investing Cash Flow
-15.3M
↓ 15.24%
Financing Cash Flow
-598.0K
↓ 62.69%
Q3 FY23Q/Q Change
Operating Cash Flow
99.1M
↑ 419.35%
Investing Cash Flow
-25.1M
↑ 64.7%
Financing Cash Flow
-7.2M
↑ 1099.33%

Technicals Summary

Sell

Neutral

Buy

Haemonetics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Haemonetics Corp
Haemonetics Corp
-14.56%
-5.8%
-16.69%
13.57%
-39.51%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
5.02%
20.15%
58.74%
31.28%
184.98%
Resmed Inc.
Resmed Inc.
16.09%
27.14%
62.7%
-17.28%
81.24%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.02%
-2.08%
-12.88%
-9.76%
-9.75%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
1.18%
-17.93%
-26.4%
-35.64%
104.36%
Alcon Ag
Alcon Ag
3.83%
8.9%
15.02%
11.44%
61.54%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Haemonetics Corp
Haemonetics Corp
33.44
33.44
1.19
3.96
0.13
0.06
NA
17.7
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
81.91
81.91
4.06
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
35.33
35.33
2.05
7.71
0.23
0.13
0.01
33.11
Becton, Dickinson And Company
Becton, Dickinson And Company
46.72
46.72
1.08
13.11
0.06
0.03
0.02
89.5
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.71
42.71
5.15
6.51
0.2
0.11
0.0
35.49
Alcon Ag
Alcon Ag
42.64
42.64
3.53
3.05
0.05
0.03
0.0
42.35
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Haemonetics Corp
Haemonetics Corp
Buy
$3.8B
-39.51%
33.44
8.61%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$169.4B
184.98%
81.91
27.65%
Resmed Inc.
Resmed Inc.
Buy
$36.0B
81.24%
35.33
21.79%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.4B
-9.75%
46.72
7.13%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$21.8B
104.36%
42.71
18.25%
Alcon Ag
Alcon Ag
Buy
$46.7B
61.54%
42.64
11.44%

Insights on Haemonetics Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 343.29M → 336.17M (in $), with an average decrease of 2.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 20.36M → 38.37M (in $), with an average increase of 46.9% per quarter

  • Vs RMD

    In the last 1 year, Resmed Inc. has given 62.7% return, outperforming this stock by 79.4%

Institutional Holdings

  • Capital Research Global Investors

    13.51%

  • BlackRock Inc

    11.64%

  • Vanguard Group Inc

    10.04%

  • Wellington Management Company LLP

    7.50%

  • Neuberger Berman Group LLC

    7.40%

  • State Street Corporation

    3.58%

Company Information

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right

Organization
Haemonetics Corp
Employees
3657
CEO
Mr. Christopher A. Simon
Industry
Health Technology

Discover More

FAQs